Editorial: natural history of hepatitis delta virus‐induced liver disease ‐ less severe today but still needs attention

Gençdal, Genco; Zeybel, Müjdat; Yurdaydın, Cihan

doi:10.1111/apt.16527

Cited by 3 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 The reasons for less active disease in our CHD cohort may be past interferon treatment-induced partial viral response 32,33 or recent descriptions of less severe disease, 34,35 possibly as a consequence of a slower turnover of HDV in the community compared to the past. 34,36 The best performance in correctly identifying cirrhosis was obtained with TE which displayed an excellent AUROC of 0.945 for the determination of cirrhosis similar to data reported by Da et al 5 These data are also in congruent with data reported for CHB and CHC. [37][38][39] At a cut-off of 10 kPa, TE predicted cirrhosis with a sensitivity of 95% and specificity of 75%.…”

Section: Discussionsupporting

confidence: 83%

“…Similar data were reported from our group a decade earlier 31 . The reasons for less active disease in our CHD cohort may be past interferon treatment‐induced partial viral response 32,33 or recent descriptions of less severe disease, 34,35 possibly as a consequence of a slower turnover of HDV in the community compared to the past 34,36 …”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Non‐invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta

Kalkan

Yilmaz

Erdoğan

et al. 2023

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

Assessment of liver fibrosis by non‐invasive means is clinically important. Studies in chronic hepatitis delta (CHD) are scarce. We evaluated the performance of eight serum fibrosis markers [fibrosis‐4 score (FIB‐4), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AAR), age‐platelet index (API), AST‐to platelet‐ratio‐index (APRI), Goteborg University Cirrhosis Index (GUCI), Lok index, cirrhosis discriminant score (CDS) and Hui score] in CHD and chronic hepatitis B (CHB). Liver stiffness was assessed by transient elastography (TE) in CHD. The ability of fibrosis markers to detect significant fibrosis and cirrhosis were evaluated in 202 CHB and 108 CHD patients using published and new cut‐offs through receiver operating characteristics (ROC) analysis. The latter was also applied to obtain cut‐offs for TE. APRI, Fib‐4, API and Hui score were assessed for significant fibrosis, and APRI, GUCI, Lok index, CDS and AAR for cirrhosis determination. Fibrosis markers displayed weak performance in CHB for significant fibrosis with area under ROC (AUROC) curves between 0.62 and 0.71. They did slightly better for CHD. TE displayed an AUROC of 0.92 and performed better than serum fibrosis markers (p < 0.05 for fibrosis markers). For cirrhosis determination, CDS and Lok Index displayed an AUROC of 088 and 0.89 in CHB and GUCI, Lok index and APRI displayed AUROCs around 0.90 in CHD. TE displayed the best AUROC (0.95). Hence TE is superior to serum fibrosis markers for diagnosing significant liver fibrosis and cirrhosis. GUCI, Lok index and APRI displayed a reasonable performance in CHD, which needs further confirmation.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionsupporting

confidence: 82%

Non‐invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta

Kalkan

Yilmaz

Erdoğan

et al. 2023

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Even in small-scale studies performed in tertiary centers, there appears to be little effort to differentiate between these two conditions, which may be attributed to a lack of non-invasive instruments, such as the routine use of quantitative HBsAg measurements or the lack of wide-spread availability of transient elastography. On the other hand, it may also suggest that milder forms of chronic HDV may be increasing [21] , [22] , [23] , [24] . The lack of a robust and cheap biomarker availability at every clinical setting to differentiate HBeAg-negative CHB infection from HBeAg-negative (non-cirrhotic) CHB is likely one reason why there is significant heterogeneity between outpatient studies.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis delta virus infection in Turkey: A meta-analysis of prevalence

Toy,

Güler,

Somay

et al. 2024

IJID Regions

Self Cite

View full text Add to dashboard Cite

“…More recently, HDV infection has been associated with a milder course than in the past, when fulminant hepatitis and rapid progression to cirrhosis was more commonly reported; this was most likely due to more pathogenic emerging strains of HDV rapidly circulating among HBeAg-positive subjects. 70 Acute hepatitis can be either monophasic or biphasic depending on the relative titres of the two viruses, the first peak usually being caused by HBV and the second by HDV. 64 In the setting of a super-infection, HDV takes advantage of the pre-existing HBsAg and immediately establishes infection.…”

Section: Natural Historymentioning

confidence: 99%

Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus

Usai

Gill

Riddell

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Hepatitis delta virus (HDV), which causes the most severe form of viral hepatitis, is an obligated hepatitis B (HBV) satellite virus that can either infect naïve subjects simultaneously with HBV (co‐infection), or chronically infect HBV carriers (super‐infection). An estimated 12 million people are infected by HDV worldwide. Aims To summarise the most relevant aspects of the molecular biology of HDV, and to discuss the latest understanding of the induced pathology, interactions with the immune system, as well as both approved and investigational treatment options. Methods References for this review were identified through searches of PubMed with the terms “HDV” “viral hepatitis” “co‐infection” and “super‐infection,” published between 1980 and October 2021 Results The limited access to the HDV‐infected liver has hampered the investigation of the intrahepatic compartment and our understanding of the mechanisms of HDV pathogenesis. In the absence of standardised and sensitive diagnostic tools, HDV is often underdiagnosed and owing to its strong dependence on host cellular factors, the development of direct antiviral agents has been challenging. New therapeutic agents targeting different steps of the viral cycle have recently been investigated, among which bulevirtide (which was conditionally approved by EMA in July 2020) and lonafarnib; both drugs having received orphan drug designation from both the EMA and FDA. Conclusions The HBV cure programme potentially offers a unique opportunity to enhance HDV treatment strategies. In addition, a more comprehensive analysis of the intrahepatic compartment is mandated to better understand any liver‐confined interaction of HDV with the host immune system.

show abstract

Editorial: natural history of hepatitis delta virus‐induced liver disease ‐ less severe today but still needs attention

Abstract: LINKED CONTENT This article is linked to Palom et al paper. To view this article, visit https://doi.org/10.1111/apt.16485

Cited by 3 publications

References 10 publications

Non‐invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta

Non‐invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta

Hepatitis delta virus infection in Turkey: A meta-analysis of prevalence

Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus

Contact Info

Product

Resources

About